IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer

Krizia Rohena-Rivera, María M. Sánchez-Vázquez, Diana A. Aponte-Colón, Ingrid S. Forestier-Román, Mario E. Quintero-Aguiló, Magaly Martínez-Ferrer

1 Department of Biochemistry, University of Puerto Rico, School of Medicine, San Juan, Puerto Rico, 2 University of Puerto Rico Comprehensive Cancer Center San Juan, Puerto Rico, 3 Department of Pharmaceutical Sciences, University of Puerto Rico, School of Pharmacy San Juan, Puerto Rico

* magaly.martinez1@upr.edu

Abstract

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer. In the United States it is the second leading cause of cancer related deaths in men. PCa is often treated via radical prostatectomy (RP). However, 15–30% of the patients develop biochemical recurrence (i.e. increased serum prostate specific antigen (PSA) levels). Interleukin-15 (IL-15) is a secreted cytokine found over expressed in patients with recurrence-free survival after RP. In our study, we aim to determine the role of IL-15 in PCa using in vitro and in vivo models, and gene expression analysis. PC3 (androgen-independent) and 22RV1 (androgen-dependent) cell lines were treated with IL-15 at 0.0013 ng/mL and 0.1 ng/mL. Tumor growth was evaluated using an orthotopic xenograft model. The anterior prostate lobes of SCID mice were injected with 250,000 22RV1 cells and IL-15 was administered bi-weekly with intraperitoneal (IP) injections during 4 weeks. Tumor tissue was collected for immunohistochemical and gene expression analysis. To study changes in gene expression, we looked at “Tumor Metastasis” and “PI3K pathway” using commercially available PCR arrays. In addition, we employed a microarray approach using the Affymetrix Hugene 2.0 ST array chip followed by analysis with Ingenuity Pathways Analysis (IPA) software. In vitro studies showed that IL-15 decreased PCa cell motility at both concentrations. In vivo studies showed that IL-15 increased neutrophil infiltration, and the expression of adiponectin, desmin and alpha smooth muscle actin (α-sma) in the tumor tissue. Angiogenesis analysis, using CD31 immunohistochemistry, showed that IL-15 decreased the number of blood vessels. Gene expression analysis identified Cancer, Cell Death, Immune Response and Lipid Metabolism as the major diseases and functions altered in tumors treated with IL-15. This suggests that IL-15 causes inflammation and changes in stroma that can promote decreased tumor cell proliferation.
Introduction

In the United States of America, prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer, and the second leading cause of death in male patients [1]. PCa is often treated with radical prostatectomy (RP). Even though it can provide positive results, 15–30% of the patients will suffer from biochemical recurrence (BCR) or elevated blood levels of prostate specific antigen (PSA) [2,3]. BCR often develops asymptptomatically within 10 years of treatment and can occur due to cells that have metastasized to other areas [4,5]. Although BCR can be identified with elevated PSA levels, there are currently no reliable predictive biomarkers in the clinic that can be used to assess biochemical recurrence risk [5,6]. The available biomarkers and (or) clinical information are insufficient to predict recurrence and metastasis [7]. The early detection of potential metastatic or recurrent PCa through the use of novel biomarkers can lead to proactive use of adjuvant therapeutic options and better patient outcomes.

Given that inflammation plays a significant role in cancer progression, the expression of inflammatory mediators, such as cytokines, is important in PCa. Studies have found that the expression of cytokines and their receptors can vary with stage and aggressiveness, and can fluctuate during treatment [8–10]. Thus, cytokines have been implicated as potential biomarkers for predicting PCa progression and recurrence.

IL-15, a 15 kDa protein and member of the 4-alpha-helix bundle family of cytokines, is a pro inflammatory cytokine with very similar functions to Interleukin 2 (IL-2). It binds to the specific receptor IL-15Rα and activates the Jak1/Jak3/Stat5 signaling pathway [11]. IL-15 plays an important role in the maturation and proliferation of T, B and NK cells. More specifically, IL-15 increases the cytotoxicity of CD8+ T cells and is essential for NK cell activation [12]. Given its ability to attract CD8+ T cells and NK cells towards the tumor site, IL-15 has been identified as an anti-tumor cytokine in several models, including: neuroblastoma, breast and colorectal cancer [13–16]. In the context of PCa, IL-15 has been associated with recurrence-free survival after RP [17]. This suggests that IL-15 expression in the microenvironment may provide a benefit for PCa patients. Our study seeks to provide insight to the considerable gaps in the existing knowledge that connects the biologic role of IL-15 and positive outcomes in PCa patients.

In addition to inflammation, differences in gene expression patterns and genome instability are associated with cancer progression [18,19]. In PCa, one of the most studied gene mutations is the loss of phosphatase and tensin homolog (PTEN). PTEN, a tumor suppressor gene, encodes a tyrosine phosphatase that modulates cell cycle progression [20]. With mutation rates of up to 60% in localized cancer, PTEN deletion is one of the most common mutations in PCa and it is often associated with poor prognosis [21–23]. In addition to PTEN loss, other gene expression patterns have been associated with high Gleason Score and PCa relapse [24]. Thus, gene expression patterns can be used to stratify patients and to understand the mechanisms that promote PCa progression. Therefore, in this project we aim to identify, gene expression patterns affected by IL-15 in PCa.

In this study, we evaluated the role of IL-15 in migration, invasion, proliferation, tumor growth, and angiogenesis using in vitro and in vivo models of PCa. In addition we focused on gene expression changes that could predict tumor progression in the long term. We show that IL-15 decreased invasion and migration of PCa cells without affecting growth in vitro. We also demonstrate that IL-15 causes an increase in neutrophil infiltration in the tumor tissue. Moreover, adiponectin, desmin, and alpha smooth muscle actin (α-sma) expression was increased with IL-15 treatment in vivo. These findings suggest that IL-15 causes inflammation and changes in stroma that can promote a decrease in tumor cell proliferation. To investigate the effect of IL-15 in angiogenesis, we analyzed CD31 expression. We show that IL-15 decreases...
the number of blood vessels, suggesting that IL-15 decreases angiogenic potential in vivo. In summary, we show that IL-15 reduces cell migration and invasion in vitro. In addition, IL-15 reduces proliferation in vivo (as shown by pH3 expression), reduces angiogenic potential (as shown by CD31) and modifies the stroma (as shown by desmin and α-sma expression). For gene expression studies, we first looked at two specific pathways “Tumor Metastasis” and “PI3K pathway” using commercially available PCR arrays. Afterwards, we used a microarray approach with the Affymetrix Hugene 2.0 ST array chip. Data obtained from the microarray chip was analyzed with Ingenuity Pathway Analysis (IPA) software. We identified four major networks: Cancer, Cell Death, Immune Response and Lipid Metabolism. These data suggest that IL-15 treatment could inhibit PCa progression by promoting an immune response that can cause cell death. Thus, our study provides evidence that IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in PCa.

Materials and methods
The Medical Sciences Campus Institutional Animal Care and Use Committee (IACUC) approved protocol number A8700110 to perform this project.

Cell culture
PC3 (androgen independent) and 22RV1 (androgen dependent) PCa cell lines were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were cultured in complete RPMI-1640 medium (Hyclone, Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Hyclone, Waltham, MA, USA) and penicillin-streptomycin complex (1,000 units/mL) (Gibco, Life Technologies, Carlsbad, CA, USA) at 37˚C and 5% CO₂ in a humidified incubator.

Scratch wound healing assay
In 12-well tissue culture plates, PC3 cells (2 X 10⁵ cells/mL) were maintained until 95% confluent. After 24 hours of serum starvation, a wound was made in the cell monolayer using a 200 µL pipette tip. Cells were washed using PBS and treated with complete RPMI medium containing IL-15 (Genway, San Diego, CA, USA) (0.0013 ng/mL and 0.1 ng/mL), or control (PBS). Images at a 4x magnification were obtained with a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan) at 0, 12 and 24 hours of treatment. Within each wound, we analyzed 10 distance measurements using Image Pro Plus Software. The wound closure differences were normalized and compared to the control using Student’s T-test at a 95% confidence interval. Experiments were performed in triplicate.

Invasion assay
After 24 hours of serum starvation, 22RV1 and PC3 cells were seeded at a density of 4 X 10⁴ cells/mL in 24-well 8.0 µm pore transwell chambers (Corning, Corning, NY, USA) coated with laminin/entactin (Becton Dickinson, Franklin Lakes, NJ, USA). The reservoir well had complete RPMI 1640 medium with IL-15 for a final concentration of 0.0013 ng/mL or 0.1 ng/mL. Under culturing conditions (37˚C and 5% CO₂), the cells were allowed to invade during 24 hours. With a sterile cotton swab and PBS, we removed the non-invasive cells from the top chamber. Invasive cells were fixed for 30 minutes, with 10% formalin (Thermo Scientific Waltham, MA, USA) and stained over night with hematoxylin (American Master Tech, Lodi, CA, USA). The membranes were washed with water and mounted on slides. Photographs at a 4x magnification were captured with a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan).
The number of invasive cells was counted using Image Pro Plus Software. Results were analyzed using the Student’s T-test at a 95% confidence interval. All experiments were performed in triplicate.

**Orthotopic mouse model**

Male ICR-SCID mice (IcrTac:IcrCrl-SCID) (Taconic, Germantown, NY, USA) (7–8 weeks old) were kept in a pathogen-free environment under the Institutional Animal Care and Use Committee regulations at The University of Puerto Rico Medical Sciences Campus animal facility (protocol #A8700110). Mice received food and water ad libitum with a 12-hour light cycle. To develop 2 prostate tumors per mouse, we performed an orthotopic xenograft model in which 22RV1 (250,000 cells) were injected in the anterior prostate lobes of ICR-SCID mice. To reduce leakage in the peritoneal cavity during surgery, cell suspensions in PBS were placed in 30 μL of collagen I (Becton Dickinson, Franklin Lakes, NJ, USA) and allowed to partially solidify. IL-15 (0.0013 ng/mL) or vehicle (Saline) was administered bi-weekly with intraperitoneal injections during 4 weeks. In total, the control group had 13 mice and the IL-15 group had 10 mice. Each mouse yielded 2 tumors. Tumor volume was determined using caliper measurements. Results were analyzed using the Student’s T-test at a 95% confidence interval. To evaluate metastasis, we collected lung, liver, and spleen organs. We performed gross examination for visible nodules and hematoxylin eosin staining to certify any metastatic lesions.

**Tissue collection and processing**

Tumor samples (n\textsubscript{control} = 26 tumors, n\textsubscript{IL-15} = 20 tumors) were divided in two sections. One was frozen in dry ice and stored at -80°C, while the other was fixed in 10% buffered formalin. The frozen tissue section was used to isolate RNA for gene expression assays. The fixed tissue was processed and paraffin-embedded.

**Hematoxylin-eosin staining**

For histological examination, 5 μm sections of formalin-fixed paraffin-embedded (FFPE) tissue were deparaffinized in xylene and hydrated using serial descending concentrations of alcohol. Staining with hematoxylin was followed by stain differentiation with 1% v/v acid alcohol (80% ethanol, 19% deionized water, 1% HCl), 0.3% v/v ammonia water (0.3% NH₄OH in deionized H₂O) and washing with 70% ethanol. After eosin staining (0.05% Eosin Y in 70% Ethanol-0.005% acetic acid) the tissue sections were dehydrated with increasing serial dilutions of ethanol and xylene. Slides were mounted using permount mounting medium. n = 5 representative tumors per group.

**Immunohistochemistry and immunofluorescence**

FFPE tumor samples were dewaxed in xylene and rehydrated in descending concentrations of alcohol. Antigen retrieval was performed using heat and a citrate-based Antigen Unmasking Solution (1:100 dilution) (Vector Laboratories, Burlingame, Ca, USA). Endogenous peroxidase was quenched with 3% v/v H₂O₂. The primary antibodies used were: phospho-histone 3 (pH3) (1:1000 dilution) (Abcam, Cambridge; MA, USA), CD31 (1:50 dilution) (Abcam, Cambridge; MA, USA), desmin (1:1000 dilution) (Santa Cruz Biotecology, Santa Cruz, CA, USA), alpha-smooth muscle actin (a-sma) (1:25 dilution) (Thermo Scientific Waltham, MA, USA), adiponectin (1:100 dilution) (Abcam, Cambridge; MA, USA), and neutrophil elastase (1:1000 dilution) (Abcam, Cambridge; MA, USA). All immunohistochemistry was detected using Dako Envision system-HRP (DAB) (anti-rabbit) (Dako; Glostrup, Denmark) or Dako LSAB
System-HRP (DAB) (anti-mouse) (Dako; Glostrup, Denmark) according to the manufacturer's instructions. Hematoxylin was used as a counterstain. For immunofluorescence, the secondary antibody used was Alexa-Fluor 594 (anti-rabbit) 1:2000 (Molecular Probes, Life Technologies, Carlsbad, CA, USA) and nuclei were stained with DAPI 1:5000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). To quantify pH3, desmin, a-sm and adiponectin, a subjective scale from 1–4 was used. Here, we gave a score of one (1) if 25% or less of the tumor cells were stained, a score of two (2) if 26% to 50% of the tumor cells were stained, a score of three (3) if 51% to 75% of the tumor cells were stained, and a score of four (4) if more than 75% of the tumor cells were stained. Score was given in a blind manner. N = 5 representative tumors per group. To quantify CD31, a set of 3 random fields was chosen per slide and the total number of blood vessels was counted. To quantify neutrophil elastase, 3 random fields were chosen per slide and the total number of positive cells was counted. Statistical analysis was done using the Student’s T-test at a 95% confidence interval. n = 5 representative tumors per group.

PCR array analysis
To evaluate changes in gene expression the Qiagen RT² PCR arrays (human tumor metastasis and PI3K pathway) were used (Qiagen Inc., Valencia; CA, USA). RNA (2 μg per array) was reverse transcribed using the RT² First Strand Kit including DNA elimination procedure (Qiagen Inc., Valencia; CA, USA). Results were analyzed using the MS Excel based tool provided by Qiagen (PCR Array Analysis V4, available for download at https://www.qiagen.com/us/resources/resourcedetail?id=d8d1813e-e5ba-4d29-8df0-07a3f4227e0a&lang=en). We used was a standard two-step SYBR green amplification cycle (95˚C for 15 seconds and 60˚C for 1 minute). n = 3 tumors per group, randomly chosen.

Microarray analysis
Affymetrix Hugene 2.0 chip based transcript profiling was performed at the RCMI Center for Genomics in Health disparities and Rare Diseases (University of Puerto Rico, Medical Sciences Campus). Following quality control, the RNA was prepared for microarray analysis using the standard Affymetrix protocol (Affymetrix Inc, Santa Clara, CA). Total RNA (100 ng) was converted to cDNA and amplified using T7 oligo dT and the GeneChip® WT cDNA Synthesis Kit, the GeneChip® WT cDNA Amplification Kit, and the GeneChip® Sample Cleanup Module as described in the GeneChip® Whole Transcript (WT) Sense Target Labeling Assay Manual Addendum. All quality control steps were followed to ensure that the RNA was adequate for later use in the first strand cDNA synthesis (where 10 μg are required), that the yield of cDNA was ≥ 5.5 μg of Single-Stranded DNA and that the fragmentation step worked properly by size analysis with the RNA 6000 Nano LabChip Kit in the Agilent Bioanalyzer. A gel-shift analysis of the WT (Whole Transcript) was done to assess the labeling efficiency of the fragmented cDNAs. The image data was normalized using the Expression Console software provided by Affymetrix. The mode of analysis used was Gene Level RMA sketch (S7–S10 Files). The QC metrics were verified to certify that the hybridization was performed correctly (S11 File). The intensity boxplot was observed to ensure that all samples had uniform intensity values to proceed with the analysis (S5 Fig). The signal distribution among arrays was observed to certify that all arrays exhibit a uniform signal distribution (S6 Fig). Gene expression values and clustering was done using the Transcriptome Analysis Console also provided by Affymetrix. The settings used to identify differences in expression were, a fold change higher that 2 or lower than -2 and a p value lower than 0.05. Identification of gene expression patterns was done with IPA software. The settings for this final analysis were a fold change higher than 1.5 or lower than -1.5 and a p value lower than 0.05. To identify the affected functions and
networks we used the “diseases and functions” sections of the IPA software. We selected the complete array of functions and selected the top four representative functions based on score. Data was documented according to the MIAME guidelines [25]. To see detailed information of this procedure look at the supplementary information (S1 File).

Real time PCR validation

To validate PCR array and microarray results, quantitative Real time PCR (qRT-PCR) was performed under standard conditions using the Step One Plus Real-time PCR System (Applied Biosystems, Carlsbad; CA, USA). For each gene of interest (GOI), the primers were designed with the Integrated DNA Technologies (IDT) Primer Quest tool. To ensure specificity, we performed a BLAST for each sequence. Real-time PCR was performed in 10 μL reactions using SYBR super mix (Bio-Rad, Hercules, CA, USA). Depending on the GOI, the cycle used was, 95˚C for 15 seconds and 62˚C for 1 minute or 95˚C for 15 seconds and 56˚C for 1 minute. PCR efficiency was examined and the melting curve data was collected for PCR specificity. The housekeeping gene used was GAPDH. Quantification was done using the ΔΔCt method. No PCR product was detected in control samples in which the template was omitted. Statistical analysis was done with a Mann-Whitney U test at a 95% confidence interval. (n = 5 tumors per group).

Statistical analysis

All experimental procedures were performed in triplicate. In vitro and immunostaining procedures were analyzed using a student T-test. Real time PCR results were analyzed using a Mann Whitney U test. All statistical procedures were performed with the GraphPad Prism Software (GraphPad Software, Inc CA, USA). Significance for all assays was accepted at a 95% confidence interval (P < 0.05).

Results

IL-15 decreases prostate cancer cell motility and invasion

To determine the effect of IL-15 in cell motility, we performed a wound-healing assay. PC3 cells were cultured to confluence. The monolayer was wounded and allowed to migrate for 12 and 24 hours with PBS (control), IL-15 at 0.0013 ng/mL and IL-15 at 0.1 ng/mL. After 12 hours, IL-15 treatment at 0.0013 ng/mL and 0.1 ng/mL reduced the migration of PC3 cells by 30% when compared to control (P < 0.05) (Fig 1). At 24 hours, the migration of PC3 cells was reduced by 20% in cells treated with IL-15 at 0.0013 ng/mL and IL-15 at 0.1 ng/mL when compared to control. 22RV1 cells were not used for the wound-healing assay because these cells do not grow in a confluent monolayer.

To study cell invasion, we performed a boyden chamber assay during 24 hours. We found that IL-15 at 0.0013 ng/mL and 0.1 ng/mL reduced the invasion of both PC3 and 22RV1 cells by 50% (P < 0.05) (Fig 2). Additionally, we studied cell growth using an MTS-based assay. We found no significant differences for either PC3 or 22RV1 cell lines (Data not shown). These results show that IL-15 inhibits cancer cell motility and invasion in PCa cells while cell growth remained unaffected.

IL-15 increases tumor volume without promoting cancer cell proliferation or angiogenesis

The effect of IL-15 in tumor growth was studied using an orthotopic model in which the anterior prostate lobes of SCID mice were injected with 250,000 22RV1 cells in a collagen-1/PBS
suspension. Chemokine treatment proceeded during four weeks with bi-weekly intraperitoneal injections of saline solution for the control group and IL-15 0.0013 ng/mL solution for the treatment group. Mice treated with IL-15 intraperitoneal injections (0.001 ng/mL) developed significantly larger tumors when compared to the control (P < 0.05) (Fig 3).

Fig 1. IL-15 decreases PC3 cell migration in vitro. (A) Representative 4x magnification images at 0, 12, and 24 hours (top to bottom). (B) Statistical analysis shows that IL-15 treatment causes a significant decrease in cell migration at 12 hours (top) and 24 hours (bottom). Mean ± SEM (*P < 0.05).

https://doi.org/10.1371/journal.pone.0172786.g001

Fig 2. IL-15 decreases PC3 and 22RV1 cell invasion in vitro. (A) Representative 10x magnification images of invasive cells at 24h. PC3 (Top) 22RV1 (Bottom) (B) Statistical analysis shows that IL-15 treatment causes a significant decrease in cell invasion. PC3 (Top) 22RV1 (Bottom). Mean ± SEM (*P < 0.05).

https://doi.org/10.1371/journal.pone.0172786.g002
Pathological, histological and immunohistochemical analysis of collected tumor tissue was used to study the effect of IL-15 in tumor biology. Slides were examined by a pathologist at low, medium and high power under a compound light microscope. Tumor assessment was made as described by Lsaacs and Hukku [26]. Tumors were classified in four categories by degree of differentiation: well-differentiated, moderately-differentiated, poorly-differentiated, and anaplastic. Well-differentiated tumors are characterized by the presence of glandular structures, lumen, basement membrane, and stroma. Moderately-differentiated tumors are characterized by smaller glandular structures with the lumen obstructed by tumor cells. However, the basement membrane and stroma remained intact. Tumors classified as poorly-differentiated have absence of glandular structures, basement membrane, and do not show a

![Fig 3. IL-15 increases tumor volume.](A) Representative photographs of murine tumor tissue treated with IL-15 (0.0013 ng/mL) and control. (B) Statistical analysis shows that IL-15 increased tumor volume at 0.0013ng/mL. N_{control} = 26, N_{IL-15} = 20. Mean + SEM (*P<0.05).](https://doi.org/10.1371/journal.pone.0172786.g003)
consistent relationship between tumor cells and stroma. Individual tumor cells, however, still show a normal nucleus to cytoplasm ratio. Tumors classified as anaplastic lack appearance of tissue organization and individual tumor cells show irregular nucleus size and abnormal nucleus to cytoplasm ratio. All tumor samples, regardless of the treatment, were classified as histologically anaplastic showing no significant differences among treatments (Fig 4). To determine if IL-15 increased tumor volume by increasing cell proliferation in vivo, we measured the expression of phospho-histone 3 (pH3), desmin, and alpha smooth muscle actin (α-sma), (top to bottom). IL-15 treatment decreased the expression of pH3, and increased the expression of desmin and α-sma. n = 10 tumors per group. Scale bar (H&E, pH3, and desmin) = 20 μm (40x), Scale bar (α-sma) = 50 μm (20x) Mean + SEM (*P<0.05)

https://doi.org/10.1371/journal.pone.0172786.g004

**Fig 4. IL-15 treatment affects expression of pH3, desmin and α-sma in vivo.** Tumor tissue was evaluated pathologically and immunohistochemically. Pathological analysis was done with hematoxylin-eosin staining (top pane) and immunohistochemistry was done to evaluate the expression of phospho-histone 3 (pH3), desmin, and alpha smooth muscle actin (α-sma), (top to bottom). IL-15 treatment decreased the expression of pH3, and increased the expression of desmin and α-sma. n = 10 tumors per group. Scale bar (H&E, pH3, and desmin) = 20 μm (40x), Scale bar (α-sma) = 50 μm (20x) Mean + SEM (*P<0.05)
at 0.0013 ng/mL significantly decreased the number of blood vessels in tumor tissue (P < 0.05) (Fig 5B). These results show that IL-15 increased tumor volume, however, the number of actively proliferating cells and the amount of blood vessels were significantly decreased. Additionally, we observed changes in stroma with the increased expression of desmin and α-smooth muscle actin. These data suggest that increase in tumor volume may be caused by factors unrelated to cancer progression.

IL-15 increases lipid deposition and inflammation, which contributes to an increase in tumor volume

After observing decreased cancer cell proliferation and angiogenesis in mice treated with IL-15, we hypothesized that increased tumor growth could be attributed to other factors. During gross examination, tumors generated under IL-15 treatment appeared fattier than control tumors. As a result, we decided to look for lipid deposition. A pathologist examined the slides and identified adipocytes as empty spaces of lipid droplets. Tumors generated in mice treated with IL-15 at 0.0013 ng/mL had increased number of adipocytes infiltrating the tumor cells (Fig 6A, top panel). To determine if IL-15 increases lipid mobilization and metabolism we verified adiponectin (adipoq) expression using immunohistochemistry. Our results show that IL-15 significantly increases the expression of adiponectin in vivo (Fig 6B, bottom panel). Additionally, given that IL-15 is a pro-inflammatory cytokine, we examined the tumors for signs of inflammation. Slides were examined for the presence of neutrophils which appear as multinucleated cells. Upon examination, we observed that IL-15 treatment at 0.0013 ng/mL increases the number of neutrophils. In addition, we observed that the neutrophils were infiltrating the tumor (Fig 7A). Furthermore, to examine the expression of neutrophil elastase we performed IHC. Our results confirm that IL-15 significantly increases the expression of neutrophil elastase in vivo (Fig 7B). These results suggest that IL-15 increases tumor volume by promoting lipid deposition, lipid metabolism, and inflammation.
IL-15 treatment leads to deregulation of genes involved in metastasis and the PI3K pathway

After observing decreased cell motility and angiogenesis as a result of IL-15 treatment, we decided to assess the changes in gene expression using a PCR array approach. We focused on tumor metastasis and the PI3K pathway. Results from these arrays suggest that IL-15 affected the expression of MMPs and TIMPs associated with tumor metastasis (Table 1). In addition, IL-15 also modulates several genes associated with the PI3K pathway (Table 2). We confirmed these changes in gene expression through real time PCR. The primer sequences used for qRT-PCR are listed in Table 3.

Results from real time PCR confirmation show that IL-15 caused no significant changes in the expression of matrix metallopeptidase 2 (MMP2) and matrix metallopeptidase 11 (MMP11), and TIMP metallopeptidase inhibitor 3 (TIMP3). Although changes in matrix metallopeptidase 9 (MMP9) and matrix metallopeptidase 7 (MMP7) were not statistically significant, the expression was different. Nevertheless, one natural inhibitor of these proteases, TIMP metallopeptidase inhibitor 2 (TIMP2) was increased. (Fig 8). In addition, IL-15 increased the expression of phos-phatase and tensin homolog (PTEN), insulin receptor substrate 1 (IRS1), insulin-like growth factor 1 (IGF1), phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG), Fas ligand (FASLG), Integrin-linked kinase (ILK), CD14 molecule (CD14) and Cyclin D1 (CCND1) (Fig 9). These results suggest that IL-15 cause changes in the stroma as shown by the differences in expression of MMPs and TIMPs. Additionally, the over expression of PTEN suggest that IL-15 could increase the expression of tumor suppression genes.

IL-15 alters the expression of genes related to cancer, cell death immune response, and lipid metabolism

To identify the effect of IL-15 in tumor biology at the genomic level, we performed microarray analysis with RNA extracted from frozen tumor samples. IL-15 treatment deregulated the
Fig 7. IL-15 increases neutrophil invasion and degranulation in vivo. (A) Representative images of 22RV1 tumors: H&E (Top panel) shows increased invading neutrophils (60x magnification) (red arrows) in IL-15; neutrophil elastase (Bottom panel) shows increased expression of Neutrophil elastase in IL-15 tumors (40x magnification). (B) Statistical analysis shows that neutrophil elastase was significantly increased with IL-15 treatment. Scale bar = 10 μm, Mean ± SEM (*P<0.05).

https://doi.org/10.1371/journal.pone.0172786.g007
expression of 917 genes classified in 4 broad diseases and functions: cancer, cell death, immune response and lipid metabolism. Interestingly, most of the genes associated with cancer, were also associated with cell death, for a total of 234 genes (Fig 10). This suggests that IL-15 treatment could promote death of cancer cells. Additionally, 60 genes were associated with cancer, cell death and immune response. Out of the 28 genes associated with lipid metabolism, 9 were associated with cell death, cancer and immune response (Fig 10). These data suggest that IL-15 activity can promote and inflammatory response that results in the death of cancer cells.

To validate the diseases and functions affected by IL-15, we performed real time PCR assays. Since we reported changes in inflammatory response and lipid metabolism in vivo, we chose to confirm these networks. For the immune response network, one relevant function was development of lymphocytes (Fig 11). We selected the following genes from this function: Phospholipase C, Gamma 2 (PLCG2), Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1), Paf1/RNA Polymerase II Complex Component (CTR9), TAP Binding Protein (TAPBP), GATA Binding Protein 3 (GATA3), Signal Transducer and Activator of Transcription 3 (STAT3), Deltex 1, E3 Ubiquitin Ligase (DTX1), Macrophage Scavenger Receptor 1 (MSR1), and Transcription Factor 4 (TCF4) based on the fold change and concordance with the

| Gene Symbol | Gene Accession Number | Description                                                                 | Fold Change |
|-------------|-----------------------|------------------------------------------------------------------------------|-------------|
| MMP2        | NM_004530             | Matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | -1.52       |
| MMP7        | NM_002423             | Matrix metalloproteinase 7 (matrilysin, uterine)                             | -1.50       |
| MMP9        | NM_004994             | Matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | 1.99       |
| MMP10       | NM_002425             | Matrix metalloproteinase 10 (stromelysin 2)                                 | -1.51       |
| MMP11       | NM_005940             | Matrix metalloproteinase 11 (stromelysin 3)                                 | -1.19x10³   |
| TIMP2       | NM_003255             | TIMP metalloproteinase inhibitor 2                                           | -1.42       |
| TIMP3       | NM_003362             | TIMP metalloproteinase inhibitor 3                                           | 21.06       |

https://doi.org/10.1371/journal.pone.0172786.t001

Table 2. PCR array: Genes associated with the PI3K pathway differentially expressed by IL-15 in vivo.

| Gene Symbol | Gene Accession Number | Description                                                                 | Fold Change | p value  |
|-------------|-----------------------|------------------------------------------------------------------------------|-------------|----------|
| AKT3        | NM_005465             | V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)       | 2.51        | 0.3835   |
| BTK         | NM_000611.2           | Bruton agammaglobulinemia tyrosine kinase                                    | 4.95        | 0.3484   |
| CCND1       | NM_053056.2           | Cyclin D1                                                                    | -3.23       | 0.0577   |
| CD14        | NM_000591.3           | CD14 molecule                                                                 | 3.75        | 0.3587   |
| FASLG       | NM_000639.2           | Fas ligand (TNF superfamily, member 6)                                       | 5.06        | 0.3478   |
| FOXO3       | NM_001455             | Forkhead box O3                                                               | -2.02       | 0.3089   |
| HSPB1       | NM_001540.3           | Heat shock 27kDa protein 1                                                    | -3.15       | 0.1417   |
| IGF1        | NM_000618             | Insulin-like growth factor 1 (somatomedin C)                                 | 6.26        | 0.1102   |
| IGF1R       | NM_000875             | Insulin-like growth factor 1 receptor                                         | -3.19       | 0.1811   |
| ILK         | NM_004517.3           | Integrin-linked kinase                                                       | -2.00       | 0.0573   |
| IRS1        | NM_005544.2           | Insulin receptor substrate 1                                                 | -2.06       | 0.2651   |
| MAP2K1      | NM_002755.3           | Mitogen-activated protein kinase kinase 1                                    | -2.00       | 0.2001   |
| PDGFRB      | NM_006206.4           | Platelet-derived growth factor receptor, alpha polypeptide                   | 5.06        | 0.3478   |
| PI3CG       | NM_002649             | Phosphoinositide-3-kinase, catalytic, gamma polypeptide                       | 5.06        | 0.3478   |
| PI3K1       | NM_181504.3           | Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                      | -2.01       | 0.0344   |
| PI3K2       | NM_005027.3           | Phosphoinositide-3-kinase, regulatory subunit 2 (beta)                       | -2.48       | 0.0404   |
| PTEN        | NM_000314             | Phosphatase and tensin homolog                                               | 3.11        | 0.1919   |
| TLR4        | NM_138554.4           | Toll-like receptor 4                                                          | 4.81        | 0.3490   |

https://doi.org/10.1371/journal.pone.0172786.t002
Within the lipid metabolism network, one relevant function was long chain fatty acid transport from which we chose these genes: Acyl-CoA Synthetase Long-Chain Family Member 3 (ACSL3), Carnitine Palmitoyltransferase 2 (CPT2), Fatty Acid Binding Protein 1 (FABP1), Fatty Acid Binding Protein 4 (FABP4), Glutamic-Oxaloacetic Transaminase 2 (GOT2), and Perilipin 2 (PLIN2) (Fig 12). The primers used for real time PCR confirmation are listed in Table 5.

Our real time PCR results for the genes associated with lymphocyte development show that, IL-15 causes a significant increase in expression of PLCG2, RAC1, GATA3, and DTX1 (Fig 13). In addition, although not statistically significant, IL15 caused an increase in expression of CTR9 and TCF4. The genes TAPBP, STAT3, and MSR1 showed no significant differences. For genes associated with lipid metabolism, real time PCR results showed that IL-15 causes a significant increase of CPT2 mRNA. Although not statistically significant (P > 0.05) we identified a notable increase of FABP4 and PLIN2, a visible decrease of ACSL3 mRNA. FABP1 and GOT2 mRNA expression was not visibly different when compared to the control. The fold change results for the real time PCR assays are in Table 6.

### Discussion

Previous work established that IL-15 over-expression is associated with recurrence-free survival [17]. Given its role in the development of NK and cytotoxic T cells, IL-15 has been identified as an anti-tumor cytokine in models for breast and colorectal cancer [14–16,28]. Although...
these data suggest that IL-15 expression may provide a benefit for PCa patients, the precise role of IL-15 in PCa progression is largely unknown. In this work, we evaluated the effects of IL-15 in PCa using in vitro and in vivo models. We focused on cell migration, invasion, tumor growth, proliferation, angiogenesis, inflammation and changes in gene expression.

The data described demonstrate that IL-15 has an effect on PCa cells regardless of androgen sensitivity. Effects were significant in PC3 cells which are androgen insensitive and 22Rv1 cells which are androgen sensitive. We observed that when cells were treated with IL-15, migration and invasion were decreased by 30% and 50% respectively. In addition, we confirmed that cell proliferation was not affected (data not shown). These data suggest that the effect we observed is specifically associated with motility and it is not affected by changes in cell growth in vitro.

Although our in vivo data shows an increase in tumor size, proliferation markers such as pH3, were decreased contrasting with our data in vitro in which growth remained unchanged. This suggests that other mechanisms caused an increase in tumor volume but inhibited PCa cell proliferation. Interestingly, we determined that IL-15 caused an increased influx of inflammatory cells to the tumor site, and an increase in adipocytes. Which caused an increase in size. In addition to proliferation we also studied metastatic potential. To do so, we evaluated desmin and a-sma expression. Unexpectedly we observed that the expression of both mesenchymal markers was increased. In addition to promoting a mesenchymal phenotype, these proteins are also stromal markers. Although the prostate stroma is mostly of muscle origin; it can become reactive as PCa progresses [29]. Reactive stroma is composed of myofibroblasts and fibroblasts stimulated to express extracellular matrix components. In comparison with the normal prostate stroma, reactive stroma tends to lose the muscle component [30,31]. Studies have characterized the different marker expression patterns that identify a reactive stroma and reports show that an increased a-sma and desmin expression in such stroma correlates with...
This suggests that IL-15 can cause changes in the stroma that promote recurrence-free survival.

Given the role of IL-15 in inflammation, we looked at the infiltration of neutrophils. Neutrophils are involved in the innate immune response, which we were able to assess in our mouse model [32]. The effects of IL-15 in neutrophil function have been studied and results show that IL-15 increases neutrophil invasion, promotes degranulation and increases IL-8 secretion [33]. IL-8 is a pro-inflammatory cytokine that also promotes neutrophil recruitment [34]. On the other hand, neutrophils are mostly unaffected by the similar cytokine, IL-2, even though they express the IL-2 receptor [33]. Therefore, neutrophils infiltration is an appropriate measure of inflammation in our model. Interestingly, we observed an increased amount of

![Cell Death vs Immune Response](image-url)

**Fig 9. qRTPCR analysis of differentially expressed genes in murine tumors treated with IL-15: PI3K PCR array.** Genes were obtained from the PI3K pathway PCR array. Real-time PCR results for: Phosphatase and tensin homolog (PTEN), Insulin receptor substrate 1 (IRS1), Insulin-like growth factor 1 receptor (IGF1R), Forkhead box O3 (FOXO3), V-akt murine thymoma viral oncogene homolog 3 (AKT3), Phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG), Phosphoinositide-3-kinase, regulatory subunit 2 (beta) (PIK3R2), Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1), Fas ligand (FASLG), Mitogen-activated protein kinase kinase 1 (MAP2K1), Integrin-linked kinase (ILK), Heat shock 27kDa protein 1 (HSPBP1), CD14 molecule (CD14), and Cyclin D1 (CCND1). Fold change calculated with the ddCT method. N = 5 representative tumor samples per treatment. Mean ± SEM. *p<0.05. Experiments performed in triplicate.

https://doi.org/10.1371/journal.pone.0172786.g009

**Fig 10. Gene expression patterns affected by IL-15 in vivo.** Microarray analysis was performed with murine tumor samples. IL-15 treatment affected the expression of 917 genes in total. These were grouped into 4 top diseases and functions: cancer, cell death, immune response, and lipid metabolism. Out of these, 575 were solely associated with Cell death, 234 were associated to cancer and cell death, and 60 were associated cancer, cell death, and immune response. Image was generated using Venny 2.1 [27]

https://doi.org/10.1371/journal.pone.0172786.g010
neutrophil infiltration in the tumor tissue when compared to the control. Moreover, we were able to verify these data with an increase in neutrophil elastase expression. Neutrophil elastase is a granulocyte-derived serine protease with a major role in host defense against microbes [35]. The fact that secreted serine proteases can regulate inflammation by increasing neutrophil infiltration has implications in tissue injury by chronic or persistent inflammation [36]. Together, these data suggest that IL-15 increased inflammation and promoted neutrophil infiltration as well as degranulation. Nevertheless, other proteases and factors are contained in the granules of neutrophils, which can also contribute to the modulation of inflammatory processes. This information can give further insight to the degree of inflammation and subsequent biological processes that affect PCa progression [36,37].
As previously mentioned, gross examination revealed that, the texture and tissue integrity of IL-15 tumors was considerably softer than control tumors. With this in mind we decided to evaluate the presence of adipocytes and lipid droplets. As predicted, we observed an increased amount of lipid droplets as well as adipocytes increased in size. We then decided to look at the expression of cytokines released by adipocytes and we were able to observe an increase in adiponectin expression. Adiponectin is a signaling molecule, also known as an adipocytokine or adipokine, which is released by adipose tissue. Although one of the functions of adiponectin is

Table 4. Microarray analysis: Genes associated with immune response and lipid metabolism functions, affected by IL-15 in vivo.

| Gene Symbol | Accession Number | Description                                                | Fold Change | p value |
|-------------|-----------------|-------------------------------------------------------------|-------------|---------|
| PLCG2       | NM_002661.4     | Phospholipase C, Gamma 2 (Phosphatidylinositol-Specific)     | 2.24        | 0.0311  |
| RAC1        | NM_006908.4     | Ras-Related C3 Botulinum Toxin Substrate 1                  | 2.01        | 0.0276  |
| CTR9        | NM_014633.4     | Paf1/RNA Polymerase II Complex Component                     | 1.87        | 0.0301  |
| TAPBP       | NM_172209.2     | TAP Binding Protein (Tapasin)                               | 1.82        | 0.0214  |
| GATA3       | NM_001002295.1  | GATA Binding Protein 3                                      | 1.81        | 0.0142  |
| STAT3       | NM_213662.1     | Signal Transducer and Activator of Transcription 3          | 1.75        | 0.0122  |
| DTX1        | NM_004416.2     | Deltex 1, E3 Ubiquitin Ligase                               | 1.63        | 0.0257  |
| MSR1        | NM_138716.2     | Macrophage Scavenger Receptor 1                             | 1.62        | 0.0311  |
| TCF4        | NM_001306208.1  | Transcription Factor 4                                      | 1.58        | 0.0273  |
| ACSL3       | NM_004457.3     | Acyl-CoA Synthetase Long-Chain Family Member 3              | -2.430      | 0.0137  |
| CPT2        | NM_000098.2     | Carnitine Palmitoyltransferase 2                            | 1.630       | 0.0496  |
| FABP1       | NM_001443.2     | Fatty Acid Binding Protein 1                                | 2.320       | 0.0184  |
| FABP4       | NM_001442.2     | Fatty Acid Binding Protein 4                                | 2.910       | 0.0321  |
| GOT2        | NM_002080.3     | Glutamic-Oxaloacetic Transaminase 2                         | 1.970       | 0.0227  |
| PLIN2       | NM_001122.3     | Perilipin 2                                                 | 2.950       | 0.0105  |

As previously mentioned, gross examination revealed that, the texture and tissue integrity of IL-15 tumors was considerably softer than control tumors. With this in mind we decided to evaluate the presence of adipocytes and lipid droplets. As predicted, we observed an increased amount of lipid droplets as well as adipocytes increased in size. We then decided to look at the expression of cytokines released by adipocytes and we were able to observe an increase in adiponectin expression. Adiponectin is a signaling molecule, also known as an adipocytokine or adipokine, which is released by adipose tissue. Although one of the functions of adiponectin is
the stimulation of lipid metabolism, it is also associated with inflammation [38,39]. In fact, adipose tissue is considered an endocrine organ capable of secreting numerous signaling molecules and promoting inflammation. Moreover, obesity and other metabolic conditions are risk factors for autoimmune diseases, chronic inflammation, and cancer [39,40]. Previous studies suggest that tumor growth can be affected by the increase in lipids. Even though adiponectin signals for lipid metabolism, previous studies have shown that lipid content does not decrease from differentiated adipocytes [41]. This fact supports our data, as we also observed an increased amount of adipocytes in our tissue samples. The role of adiponectin in cancer has been long disputed, in some models it has been linked to progress cancer, while in others it has been identified as a tumor suppressor. This disparity often relies on the cell type and the tumor microenvironment [42,43]. Nevertheless, previous studies have shown that adiponectin inhibits PCa cell growth and that lower concentrations of adiponectin are inversely correlated with PCa malignancy [44,45]. These studies support our findings, as we observed decreased expression of proliferation markers.

Using the PCR array method and real time PCR, we were able to confirm the increased expression of TIMP2. In addition, we confirmed an increase in PTEN, IRS1, IGF1, PIK3CG, FASLG, ILK, CD14, and CCND1 mRNA expression. Up to this point, the data we have gathered show that in vitro IL-15 decreases motility of PCa in vitro and increases tumor volume, inflammation and neutrophil mobility in vivo. Even though MMPs are highly associated with progressive cancer, they are also modulators of inflammatory processes [46]. The active secretion of neutrophil elastase can increase levels of MMPs [47]. To our surprise, TIMPs, natural MMP inhibitors, were also increased in our studies suggesting ECM remodeling. In addition, the increased expression of CD14, an important molecule for the modulation of the innate immune system, and FASLG are indicatives of inflammation [48]. Previous studies show that FASLG stimulates neutrophil infiltration, which supports our findings [49]. Additionally, the increased expression of ILK may suggest an inflammatory phenotype due to its implication in inflammatory cell mobilization [50]. The increase of PTEN, a tumor suppressor, shows that IL-15 may induce an anti-tumor phenotype. However, the increased expression of CCND1, IRS1 and IGF1 which are implicated in cell cycle progression suggest otherwise [51,52].
Fig 13. Real time PCR analysis of differentially expressed genes in tumors treated with IL-15. Real time PCR results for: Phospholipase C, Gamma 2 (PLCG2), Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1), Paf1/RNA Polymerase II Complex Component (CTR9), TAP.
To further investigate the gene expression patterns modulated by IL-15 we validated the expression of genes associated with lymphocyte development and lipid metabolism. Our results confirmed that IL-15 causes a significant increase in expression of PLCG2, RAC1, GATA3 and DTX1, which are associated with lymphocyte development. The increased expression of PLCG2 suggests that there is increased signaling by IL-15, thereby promoting immunity [32]. Phospholipase c gamma 2 plays an important role in lymphocyte selection during maturation as it promotes T cell receptor signal transduction [53]. In addition, PLCG2 is important for innate immunity because of its role promoting NK cell development and cytotoxicity [54]. The increased expression of RAC 1, a Rho GTPase, has been long associated with cancer progression and cell survival, reason why it is a potential therapeutic target [55,56]. However RAC has also been shown to increase immune response by promoting NK and CD8+ T cells cytotoxicity [57]. The up-regulation of GATA3 has been also associated with cancers some being of hematopoietic origin [58]. GATA3 is a transcription factor involved in the development of lymphocytes, particularly favoring a Th2 response [59,60]. Increased expression of GATA3 has been shown to be a good prognosis marker in other types of cancer such as breast. However, mutations in this gene have shown opposite outcomes [61]. DTX1 on the other hand, functions as an ubiquitin binding protein and has been shown to function in B cell maturation [62]. However, over-expression of this protein can result in T cell anergy and can promote cancer proliferation [62,63]. The confirmation of these genes suggests that IL-15 promotes inflammation. Nonetheless, more studies can be done to ensure that this expression results in an antitumor response given that some of these genes can also be associated with cancer progression.

**Conclusion**

PCa is often treated with radical prostatectomy (RP) with adjuvant therapy like radiation or chemotherapy. Even though a combinatorial treatment can provide positive results, 15–30% of
the patients will suffer from biochemical recurrence or elevated blood levels of PSA [2,3]. Although the early detection of potential metastatic or recurrent PCa can lead to proactive use of adjuvant therapeutic options, the available biomarkers and (or) clinical information are insufficient to predict recurrence and metastasis [7].

Since inflammatory processes play a significant role in cancer progression, the study of inflammatory mediators, such as cytokines, is important for PCa. Reason why, cytokines have been studied as potential biomarkers for progression and recurrence. Previous work established that IL-15 over expression was associated with recurrence-free survival suggesting that IL-15 could be a potential biomarker [17]. In this study, we evaluated several hallmarks of cancer such as: proliferation, cell motility, tumor growth, angiogenesis, inflammation and changes at the genetic level. Our data show that IL-15 decreases cell migration and invasion in vitro. Additionally, the presence of IL-15 in the tumor microenvironment, decreases proliferation, and blood vessel formation. We also observed that IL-15 increases tumor volume as a consequence of inflammation and lipid mobilization. Further in vivo studies are needed to have a better understanding given that inflammation, neutrophil infiltration and obesity are risk factors. Nevertheless, we show that IL-15 affects PCa by decreasing motility affecting inflammatory processes, and modifying gene expression. All these factors are relevant for PCa progression and should be taken into consideration while evaluating IL-15 as a biomarker and for further applications in the clinic.

Supporting information

S1 Fig. Control a sample hybridization scan. Image file generated after hybridization process of a control sample.
(JPG)

S2 Fig. Control b sample hybridization scan. Image file generated after hybridization process of a control sample.
(JPG)

S3 Fig. IL-15 a sample hybridization scan. Image file generated after hybridization process of an IL-15 sample.
(JPG)

S4 Fig. IL-15 b sample hybridization scan. Image file generated after hybridization process of an IL-15.
(JPG)

S5 Fig. Relative probe cell intensity. Relative intensity box plot per sample.
(PNG)

S6 Fig. Signal histogram. Representative image of the intensity histogram per sample.
(PNG)

S1 File. Supporting information. Detailed information pertaining the microarray experiments.
(DOCX)

S2 File. HuGENE probe sequences. The Probe Sequence files for the HuGene 2.0 array chip in FASTA format.
(ZIP)

S3 File. Control a hybridization scan raw data. Raw data obtained from hybridization scan corresponds to control sample a.
(CEL)
S4 File. Control hybridization scan raw data. Raw data obtained from hybridization scan corresponds to a control sample b.
(CEL)

S5 File. IL-15 hybridization scan raw data. Raw data obtained from hybridization scan corresponds to an IL-15 sample a.
(CEL)

S6 File. IL-15 hybridization scan raw data. Raw data obtained from hybridization scan corresponds to an IL-15 sample b.
(CEL)

S7 File. Control a normalized expression data. Normalized data obtained after Gene Level RMA sketch analysis with the Expression Console Software (Affymetrix Inc, Santa Clara, CA) (CHP)

S8 File. Control b normalized expression data. Normalized data obtained after Gene Level RMA sketch analysis with the Expression Console Software (Affymetrix Inc, Santa Clara, CA) (CHP)

S9 File. IL-15 a normalized expression data. Normalized data obtained after Gene Level RMA sketch analysis with the Expression Console Software (Affymetrix Inc, Santa Clara, CA) (CHP)

S10 File. IL-15 b normalized expression data. Normalized data obtained after Gene Level RMA sketch analysis with the Expression Console Software (Affymetrix Inc, Santa Clara, CA) (CHP)

S11 File. QC metrics summary. Tabular representation of all QC metrics.
(TXT)

S12 File. Gene expression summary. Gene level expression analysis results.
(TXT)

Acknowledgments
Special thanks to Dr. Carmen Cadilla and Jessica Renta of the RCMI Center for Genomics in Health Disparities and Rare Diseases (RCMI, Medical Science Campus, grants 8G12-MD007600 and NIMHDG: 12RR0305) for their aid with microarray experiments.

Author Contributions
Conceptualization: MMF.

Formal analysis: KRR.

Funding acquisition: MMF.

Investigation: KRR MMSV DAAC ISFR.

Methodology: MMF KRR MMSV.

Project administration: MMF.

Supervision: MMF.

Validation: KRR MMSV ISFR DAAC MEQA.
Visualization: KRR.

Writing – original draft: KRR.

Writing – review & editing: KRR MMF DAAC MMSV ISFR MEQA.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5–29. https://doi.org/10.3322/caac.21254 PMID: 25559415

2. Freedland SJ, Humphreys EB, Mangold L a, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. American Medical Association; 2005; 294: 433–9. https://doi.org/10.1001/jama.294.4.433 PMID: 16046649

3. Alva A, Hussain M. Intermittent androgen deprivation therapy in advanced prostate cancer. Curr Treat Options Oncol. 2014; 15: 127–36. https://doi.org/10.1007/s11864-013-0272-2 PMID: 24395278

4. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012; 10: 716–22. PMID: 23271258

5. Stephenson AJ, Kattan MW, Eastham J a, Dotan Z a, Bianco FJ, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24: 3973–8. https://doi.org/10.1200/JCO.2005.04.0756 PMID: 16921049

6. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8: e66855. https://doi.org/10.1371/journal.pone.0066855 PMID: 23826159

7. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer—the post PSA era. Anticancer Res. 2008; 29: 3289–98. PMID: 19661347

8. Wang J, He Q, Shao YG, Ji M. Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci. 2013; 17: 596–608. PMID: 23543442

9. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 2009; 16: 35–41. https://doi.org/10.1677/ERC-08-0109 PMID: 19566286

10. Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antitumoral activity. J Clin Invest. 2012; 122: 2221–33. https://doi.org/10.1172/JCI59535 PMID: 22565311

11. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 2012; 19: 238–46. https://doi.org/10.1038/cgt.2011.81 PMID: 22158521

12. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, et al. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene Ther. Macmillan Publishers Limited; 2014; 21: 393–401. https://doi.org/10.1038/gt.2014.10 PMID: 24572789

13. Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008; 14: 7790–7. https://doi.org/10.1158/1078-0432.CCR-08-1716 PMID: 19047106

14. Liu A, Furusato B, Ravindranath L, Chen Y, Srikantan V, McLeod DG, et al. Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis. J Zhejiang University Sci B. Zhejiang University Press; 2007; 8: 853–9. https://doi.org/10.1016/j.jzus.2007.B0853 PMID: 18257117

15. Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zghib N, Ramirez IJ, et al. Gene expression data reveal common pathways that characterize the unfilial nature of ovarian cancer. Am J Obstet Gynecol. NIH Public Access; 2013; 209: 576.e1-576.e16.
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science (80-). 1997; 275: 1943–1947.

21. Phin S, Moore MW, Cotter PD. Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 2013; 3: 240. https://doi.org/10.3389/fonc.2013.00240 PMID: 24062990

22. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem. 2006; 97: 433–447. https://doi.org/10.1002/jcb.20696 PMID: 16267836

23. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A, et al. Role of PTEN gene in progression of prostate cancer. Urol J. 2007; 4: 95–100. PMID: 17701929

24. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics. 2007; 89: 666–672. https://doi.org/10.1016/j.ygeno.2007.02.005 PMID: 17459658

25. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet. 2001; 29: 365–371. https://doi.org/10.1038/ng1201-365 PMID: 11726920

26. Lsaacs JT, Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate. 1988; 13: 165–188. PMID: 3174494

27. Oliveros JC. Venny. An interactive tool for comparing lists with Venn’s diagrams. [Internet]. Available: http://bioinfogp.cnb.csic.es/tools/venny/index.html

28. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate model. Proc Natl Acad Sci U S A. 2012; 109: 6187–92. https://doi.org/10.1073/pnas.1203479109 PMID: 22474386

29. Wu J-P, Huang W-B, Zhou H, Xu L-W, Zhao J-H, Zhu J-G, et al. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy. J Androl. Medknow Publications; 2014; 16: 710–4. https://doi.org/10.4103/1008-682X.129131 PMID: 24875819
